title: Selective inhibition of the pacemaker channel I(f) improves symptoms in severe dilated cardiomyopathy.
authors.forename: Uta C
authors.initials: UC
authors.lastname: Hoppe
authors.forename: Karl
authors.initials: K
authors.lastname: La Rosée
authors.forename: Robert
authors.initials: R
authors.lastname: Larbig
authors.forename: Erland
authors.initials: E
authors.lastname: Erdmann
mesh_terms: D000319:Adrenergic beta-Antagonists; D000368:Aged; D001552:Benzazepines / Q000494:pharmacology / Q000627:therapeutic use*; D002311:Cardiomyopathy, Dilated / Q000150:complications* / Q000188:drug therapy / Q000378:metabolism / Q000503:physiopathology; D000075202:Contraindications; D018618:Echocardiography, Doppler, Color; D004562:Electrocardiography; D005260:Female; D006329:Heart Conduction System / Q000187:drug effects* / Q000378:metabolism / Q000503:physiopathology; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D000077550:Ivabradine; D009157:Myasthenia Gravis / Q000150:complications*; D026902:Potassium Channel Blockers / Q000494:pharmacology / Q000627:therapeutic use*; D015221:Potassium Channels / Q000187:drug effects* / Q000378:metabolism; D013616:Tachycardia, Sinus / Q000188:drug therapy* / Q000209:etiology / Q000378:metabolism / Q000503:physiopathology; D016896:Treatment Outcome
chemical_list: D000319:Adrenergic beta-Antagonists; D001552:Benzazepines; D026902:Potassium Channel Blockers; D015221:Potassium Channels; D000077550:Ivabradine